Emmanuel Hanon – Senior VP, Vaccines R&D, GSK
In an exclusive interview, GSK’s Senior VP for Vaccines R&D Dr Emmanuel Hanon discusses how the sharing of GSK’s adjuvant technology with a wealth of scientific institutions and companies globally…
Address: Avenue Ariane 16 1200 Brussels Belgium
Tel: +32 (0)2 773 33 11
Web: http://www.boehringer-ingelheim.be/
The Boehringer Ingelheim group
Our group, established in Ingelheim (Germany), has 137 subsidiaries across 47 countries and approximately 41,500 employees, of which nearly 5,000 are active in research and development.
Since its foundation in 1885, the group is still wholly owned by the founding family and focused on researching, developing and producing and marketing of new products with high added value for medical use, also in veterinary medicine.
In Belgium and Luxembourg Boehringer Ingelheim employs over 250 staff working in the sales and distribution of pharmaceutical products for humans and animals and in clinical research.
With research as our main growth engine, developing our laboratories breakthrough medicines for use in diverse areas such as pneumology, cardiology, rheumatology, neurology, virology and oncology. Boehringer Ingelheim also develops products for self-medication and phyto-pharmaceuticals, and a series products for veterinary use. Our activities extend also to the chemical and biopharmaceutical manufacturing. Our main activity in Belgium includes the sale and distribution of pharmaceutical products for humans and animals, as well as clinical research.
In an exclusive interview, GSK’s Senior VP for Vaccines R&D Dr Emmanuel Hanon discusses how the sharing of GSK’s adjuvant technology with a wealth of scientific institutions and companies globally…
Veronique Walsh, General Manager of Bristol Myers Squibb (BMS) – Benelux, explains her ambition to build a new company culture following the acquisition of Celgene. Walsh also lays bare the…
Stakeholders from the Belgian parallel trade industry outline how their activities are helping to solve medicine shortages in Europe and ensure patients have access to the medicines they need. They…
Geert Van Hoof, founding general manager of Chiesi Belgium, shares the exciting milestones of the company’s first decade in Belgium, including their stunning year-on-year double-digit growth, their market leadership in…
Tanguy Schmitz, president of the Belgian Association of Parallel Importers & Exporters (BAPIE) outlines some of the recent work that the parallel distribution industry to ensure the supply of medicines…
Four Belgium country managers for some of the world’s largest pharma companies give their words of wisdom for women starting out in the industry. “Focus on your strengths” Sonja…
Filip Van de Vliet and Gérard Lefèbvre of Alter Pharma Group discuss the value that parallel importing is bringing to Belgian patients and the evolving relationship between parallel importers and…
Marijke Eyssen of the Belgian Health Care Knowledge Centre (KCE) introduces the institution’s mission, core values, how it chooses areas of research, and the crucial work the KCE does in…
Janssen in Belgium was founded in 1953 by Dr Paul Janssen, with only one thing in mind: saving people’s lives through the development of better medicines. In 1961, the company…
Professor Sylvie Rottey, president of the Belgian Society of Medical Oncology (BSMO) outlines the state of cancer care in Belgium, the country’s positioning in clinical trials for medical oncology, and…
Erik Present is president of Healixia, a newly formed association for medical professionals in Belgium. Present introduces the mission and purpose of Healixia, the work it is currently undertaking in…
Sabena Solomon, general manager of GSK Benelux, speaks about her first impressions of the Belgium market, having come from GSK Finland, and her initial priorities for leading the affiliate. Solomon…
See our Cookie Privacy Policy Here
